These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38205144)

  • 21. Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting.
    Lam JA; Lee HIS; Truong AQ; Macmadu A; Clarke JG; Rich J; Brockmann B
    J Subst Abuse Treat; 2019 Sep; 104():28-33. PubMed ID: 31370982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.
    Evans EA; Pivovarova E; Senthilkumar R; Rottapel RE; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
    Int J Drug Policy; 2023 Dec; 122():104252. PubMed ID: 37980776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 24. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 25. Expanding buprenorphine in U.S. jails: One county's response to addressing the fears of diversion.
    Whaley S; Bandara S; Taylor K; Krawczyk N
    J Subst Use Addict Treat; 2023 Mar; 146():208944. PubMed ID: 36880899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
    Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
    Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
    [No Abstract]   [Full Text] [Related]  

  • 27. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
    Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
    J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.
    Krawczyk N; Bandara S; Merritt S; Shah H; Duncan A; McEntee B; Schiff M; Ahmad NJ; Whaley S; Latimore A; Saloner B
    Addict Sci Clin Pract; 2022 Jun; 17(1):30. PubMed ID: 35655293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
    Harrington C; Bailey A; Delorme E; Hano S; Evans EA
    Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
    [No Abstract]   [Full Text] [Related]  

  • 30. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study.
    Macmadu A; Adams JW; Bessey SE; Brinkley-Rubinstein L; Martin RA; Clarke JG; Green TC; Rich JD; Marshall BDL
    Int J Drug Policy; 2021 May; 91():102841. PubMed ID: 32712165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.
    Ryan DA; Montoya ID; Koutoujian PJ; Siddiqi K; Hayes E; Jeng PJ; Cadet T; McCollister KE; Murphy SM
    J Subst Use Addict Treat; 2023 Mar; 146():208943. PubMed ID: 36880906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative attitudes about medications for opioid use disorder among criminal legal staff.
    Moore KE; Siebert SL; Kromash R; Owens MD; Allen DC
    Drug Alcohol Depend Rep; 2022 Jun; 3():100056. PubMed ID: 36845981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    J Subst Use Addict Treat; 2024 Mar; 158():209254. PubMed ID: 38072387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.
    Evans EA; Pivovarova E; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
    J Subst Abuse Treat; 2022 Jul; 138():108746. PubMed ID: 35249789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
    Scott CK; Grella CE; Dennis ML; Carnevale J; LaVallee R
    Health Justice; 2022 Dec; 10(1):36. PubMed ID: 36538121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
    McCann NC; LaRochelle MR; Morgan JR
    J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.